We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Grants Fast-Track Status to Genta’s, Allon’s Drugs
FDA Grants Fast-Track Status to Genta’s, Allon’s Drugs
April 9, 2010
The FDA has granted fast-track status to Genta’s gastric cancer treatment tesetaxel and Allon Therapeutics’ neuroprotective drug davunetide.